← Leaderboards
Loren G Miller
La Biomed Res Inst/ Harbor Ucla Med Ctr
$8,117,305
Attributed
$8,117,305
Total exposure
7
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.2M · FY2005–22$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
Funding mix
By agency
NIH$6,643,316 · 6
CDC$1,473,989 · 1
By mechanism
U01$6,961,138 · 2
K23$669,600 · 1
M01$486,567 · 4
Top collaborators
No co-investigators on record.
Most similar at La Biomed Res Inst/ Harbor Ucla Med Ctr
Same institution · by research overlap
- Yutaka Niihara$901,548
- Kelly D Young$942,540
- Michael Shabot$238,960
Others in their field
Top investigators on “Urinary Tract Infection”
- Scott J Hultgren · Washington University$42,943,440
- Margaret Rita Karagas · Dartmouth College$30,772,632
- Harry L. Mobley · University Of Maryland Baltimore$20,366,606
- Evgeni Veniaminovic Sokurenko · University Of Washington$15,787,865
- Theoklis Zaoutis · Children'S Hosp Of Philadelphia$15,187,649
- Ashlee Miriam Earl · University Of California-Irvine$12,588,978
Research focus
Urinary Tract InfectionClinical ResearchHuman SubjectUrinalysisCandidiasisMycosisNosocomial InfectionsStaphylococcus AureusPlacebosSoft Tissue InfectionsInfectious Skin DiseasesResistanceIncision And DrainageAntibioticsCommunitiesAdultChildClindamycinDrug ResistanceEpidemiologyInfectionClinical TrialsNosocomial Infection ControlAllergic
Grant awards (19)
Short and long term outcomes of doxycycline versus TMP-SMX for SSTI treatment$1,002,378
U01 · FY2022 · AI · contact PI
Short and long term outcomes of doxycycline versus TMP-SMX for SSTI treatment$1,083,522
U01 · FY2021 · AI · contact PI
Short and long term outcomes of doxycycline versus TMP-SMX for SSTI treatment$1,106,595
U01 · FY2020 · AI · contact PI
Short and long term outcomes of doxycycline versus TMP-SMX for SSTI treatment$1,107,689
U01 · FY2019 · AI · contact PI
Short and long term outcomes of doxycycline versus TMP-SMX for SSTI treatment$1,186,965
U01 · FY2018 · AI · contact PI
RANDOMIZED, DOUBLE-BLIND TRIAL OF CLINDAMYCIN, TRIMETHOPRIM-SULFAMETHOXAZOLE, OR$308,708
M01 · FY2010 · RR · contact PI
A Randomized Clinical Trial to Prevent Recurrent CA-MRASA Infection$175,000
U01 · FY2009 · CI · contact PI
A Randomized Clinical Trial to Prevent Recurrent CA-MRASA Infection$498,996
U01 · FY2008 · CI · contact PI
A Randomized Clinical Trial to Prevent Recurrent CA-MRASA Infection$499,994
U01 · FY2007 · CI · contact PI
A Randomized Clinical Trial to Prevent Recurrent CA-MRASA Infection$299,999
U01 · FY2006 · CI · contact PI
COMMUNITY-ASSOCIATED MRSA COLONIZATION AMONG HIV+ MEN$5,132
M01 · FY2006 · RR · contact PI
THE SIGNIFICANCE OF FUNGURIA IN HOSPITALIZED PATIENTS$3,740
M01 · FY2006 · RR · contact PI
THE SIGNIFICANCE OF FUNGURIA IN HOSPITALIZED PATIENTS$71,935
M01 · FY2005 · RR
THE SIGNIFICANCE OF FUNGURIA IN HOSPITALIZED PATIENTS$133,920
K23 · FY2004 · AI
Significance of Funguria in Hospitalized Patients$97,052
M01 · FY2004 · RR
THE SIGNIFICANCE OF FUNGURIA IN HOSPITALIZED PATIENTS$133,920
K23 · FY2003 · AI
THE SIGNIFICANCE OF FUNGURIA IN HOSPITALIZED PATIENTS$133,920
K23 · FY2002 · AI
THE SIGNIFICANCE OF FUNGURIA IN HOSPITALIZED PATIENTS$133,920
K23 · FY2001 · AI
THE SIGNIFICANCE OF FUNGURIA IN HOSPITALIZED PATIENTS$133,920
K23 · FY2000 · AI